Screener
Nektar Therapeutics NKTR Cash, Cash Equivalents, and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.
The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-212596
| Line item | Fair Value Hierarchy Level | March 31, 2026 / Amortized Cost | March 31, 2026 / Gross Unrealized Gains | March 31, 2026 / Gross Unrealized Losses | March 31, 2026 / Fair Value | December 31, 2025 / Fair Value |
|---|---|---|---|---|---|---|
| Corporate notes and bonds | 2 | $288,887 | $2 | $(723) | $288,166 | $59,785 |
| Corporate commercial paper | 2 | 401,816 | 1 | (307) | 401,510 | 156,714 |
| Obligations of U.S. government agencies | 2 | 4,490 | — | (7) | 4,483 | — |
| Available-for-sale investments | $695,193 | $3 | $(1,037) | $694,159 | $216,499 | |
| Money market funds | 1 | 17,710 | 11,919 | |||
| Certificates of deposit | 2 | 14,029 | 14,138 | |||
| Cash | N/A | 5,699 | 3,196 | |||
| Total cash and investments in marketable securities | $731,597 | $245,752 |
Item 1. Condensed Consolidated Financial Statements—Unaudited:
FAQ
- What is Nektar Therapeutics's cash, cash equivalents, and marketable securities?
- Nektar Therapeutics (NKTR) reported cash, cash equivalents, and marketable securities of $694.16M in Q1 2026.
- How has Nektar Therapeutics's cash, cash equivalents, and marketable securities changed year-over-year?
- Nektar Therapeutics's cash, cash equivalents, and marketable securities increased by 280.3% year-over-year, from $182.55M to $694.16M.
- What does cash, cash equivalents, and marketable securities mean?
- This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.
Ask your AI about Nektar Therapeutics's cash, cash equivalents, and marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude